logo
  

Why NeuroSense Therapeutics Is Rising In Pre-market?

NeuroSense Therapeutics Ltd. (NRSN) reported results from a biomarker study conducted to evaluate the potential of CogniC, the company's combination drug for the treatment of Alzheimer's disease. The company said the biomarker study identified several biomarkers associated with AD, which indicate CogniC's mechanism of action may be effective in targeting the pathways involved in the disease.

"Having identified these promising biomarkers, which have the potential to be modulated by CogniC, we are now preparing to carry out a clinical proof-of-concept study in conjunction with a leading AD clinic. The study is expected to commence in 2023," said CEO, Alon Ben-Noon.

Shares of NeuroSense Therapeutics are up 62% in pre-market trade on Thursday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Activity in the U.S. manufacturing sector slowed by more than expected in the month of September but still saw continued growth, according to a report released by the Institute for Supply Management on Monday. Stocks have moved sharply higher in morning trading on Monday, regaining ground following a dismal September. The major averages have all shown substantial moves to the upside. Swedish geneticist Svante Paabo has won this year's Nobel Prize in Physiology/Medicine for his discoveries concerning the genomes of extinct hominins and human evolution. Through his pioneering research, Svante Pääbo accomplished something seemingly impossible: sequencing the genome of the Neanderthal, an extinct relative of present-day humans. He also made the sensational discovery of a previous
Follow RTT